TOKYO Moderna (NASDAQ:MRNA) Inc. CEO Stephane Bancel said on Wednesday that the company has thought since the start of the COVID-19 pandemic that BioNTech SE (NASDAQ:BNTX) used its intellectual property to make a competing vaccine.
Last month, Moderna sued BioNTech and its partner Pfizer Inc. (NYSE:PFE) for patent infringement in the making of the first COVID-19 vaccine that was approved in the US.
Related: The COVID variant vaccine will be ready to ship in August, says the CEO of Moderna.
Bancel said in Tokyo that Moderna is thinking about building factories in Japan to make products from mRNA.
